Table 5.
Mean changes in laboratory parameter levels from baseline to exposure period
| Laboratory parameters | Imidapri | Amlodipine | p value | ||||
|---|---|---|---|---|---|---|---|
| N | LS mean | 95% CI | N | LS mean | 95% CI | ||
| ∆Creatinine (mg/dL) | 57 | 0.053 | (0.03, 0.08) | 57 | 0.0084 | (−0.02, 0.03) | 0.0138* |
| ∆eGFR (mL/min/1.73 m2) | 57 | −6.17 | (−9.53, −2.81) | 57 | 1.01 | (−2.35, 4.37) | 0.0045* |
| ∆BUN (mg/dL) | 56 | 0.31 | (−0.8, 1.41) | 55 | 1.20 | (0.08, 2.32) | 0.2788 |
| ∆Sodium (mEq/L) | 54 | 0.62 | (−0.31, 1.55) | 52 | 0.32 | (−0.64, 1.27) | 0.66 |
| ∆Potassium (mEq/L) | 54 | 0.20 | (0.06, 0.34) | 52 | −0.05 | (−0.19, 0.09) | 0.0172* |
eGFR estimated glomerular filtration rate, BUN blood urea nitrogen, LS mean least-square mean, CI confidence interval, Δ mean change in renal parameter level during exposure period from baseline
* p < 0.05 (imidapril vs amlodipine). Analyses were adjusted for covariates including age, sex, medical history and previous medication